Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.32 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.31 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.31 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888868 | 0.97 | ADRB1 (0.33) | ADRB1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL104919 | 0.97 | ADRB1 (0.33) | ADRB1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL14805909 | 0.94 | HIF1A (0.35) | ADRB1GRIN2DGRIN3BCHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL2422010 | 0.94 | HPGD (0.33) | ADRB1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL22375421 | 0.94 | HIF1A (0.35) | ADRB1GRIN2DGRIN3BCHRM2CHRM1 | |
| Methylamine SCHEMBL11757130 | 0.92 | GRIN2D (0.34) | ADRB1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL39972 | 0.87 | CXCR4 (0.35) | CHRM2CHRM1 | |
| SCHEMBL22096085 | 0.87 | — | — | |
| SCHEMBL25753249 | 0.87 | — | — | |
| Bicarbonate SCHEMBL6297564 | 0.85 | CA2 (0.38) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-01-09 | — | — | US | disclosed |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | disclosed |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-07-06 | — | — | US | disclosed |
| US-9637497-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | Nerviano Medical Sciences, S.R.L. (IT) | 2017-05-02 | — | — | US | disclosed |
| US-20170050972-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-02-23 | — | — | US | disclosed |
| US-9464090-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-11 | — | — | US | disclosed |
| US-20150158876-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-06-11 | — | — | US | disclosed |
| US-8981089-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-17 | — | — | US | disclosed |
| EP-1636236-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-03-22 | — | — | EP | disclosed |
| US-20050282862-A1 | Aromatic amides | BEIGHT DOUGLAS W | 2005-12-22 | — | — | US | disclosed |
| WO-2004104007-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-12-02 | — | — | WO | disclosed |
| EP-1140903-B1 | AROMATIC AMIDES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6759414-B2 | ANTICOAGULANTS WHICH ACT SELECTIVELY ON FACTOR XA; FAST ACTING; ORAL; DO NOT INTERFERE WITH LYSIS OF BLOOD CLOTS | ELI LILLY AND COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20040029874-A1 | Aromatic amides | BEIGHT DOUGLAS WADE (US) | 2004-02-12 | — | — | US | disclosed |
| US-6635657-B1 | Pyridine derivatives; anticoagulants | ELI LILLY AND COMPANY | 2003-10-21 | — | — | US | disclosed |
| WO-2002023784-A2 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1140903-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039118-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ADRB1 1777/4885CHRM2 4084/4885GRIN2A 3597/4885 |
| US-20040029874-A1 | Aromatic amides | F11, F12, F5 | ADRB1 944/4885CHRM2 3401/4885GRIN2A 4678/4885 |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ADRB1 1784/4885CHRM2 4061/4885GRIN2A 3594/4885 |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP4K2 | ADRB1 1784/4885CHRM2 4061/4885GRIN2A 3594/4885 |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ADRB1 1784/4885CHRM2 4061/4885GRIN2A 3594/4885 |
| US-20150158876-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ADRB1 1784/4885CHRM2 4061/4885GRIN2A 3594/4885 |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ADRB1 1777/4885CHRM2 4084/4885GRIN2A 3597/4885 |
| US-20050282862-A1 | Aromatic amides | F11, F12, F5 | ADRB1 944/4885CHRM2 3401/4885GRIN2A 4678/4885 |
| US-20170050972-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ADRB1 1784/4885CHRM2 4061/4885GRIN2A 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.